QurAlis Corporation, a Cambridge, MA-based biotech company focused on developing precision therapeutics for ALS and other neurological diseases, is raising a seed extension, bringing the total funding to date to $5.5m.
BioInnovation Capital and Viva Biotech Limited joined existing biotech investors MP Healthcare Venture Management (MPH), and Amgen Ventures. Along with this financing, Jeffrey Moore, D.Phil., M.B.A., President of MPH and Johannes Fruehauf, M.D., Ph.D., General Partner at BioInnovation Capital, are joining QurAlis’ Board of Directors.
The company has also won a Pfizer-sponsored Golden Ticket, and is now a resident company of Johnson & Johnson Innovation, JLABS (JLABS).
The funding and additional support will allow QurAlis to advance its preclinical research in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) toward the clinic.
Led by Kasper Roet, Ph.D., CEO, QurAlis is a biotech company focused on developing precision therapeutics for ALS and other neurological diseases.
The Golden Ticket provides the company with equipped, permitted and supported lab space for biomedical research in LabCentral, in addition to programming and networking opportunities. Each Golden Ticket also provides a spot on a priority waitlist for residency and a voucher for prepaid rent for one year.